Cargando…
Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
Throughout the last decades, newly developed chemotherapeutic agents and immunotherapies that target signaling pathways have provided patients with better prognoses, improved their quality of life and increased survival rates, thus converting cancer to a stable chronic disease. However, non-anthracy...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953347/ https://www.ncbi.nlm.nih.gov/pubmed/35323614 http://dx.doi.org/10.3390/jcdd9030066 |
_version_ | 1784675828471169024 |
---|---|
author | Briasoulis, Alexandros Chasouraki, Angeliki Sianis, Alexandros Panagiotou, Nikolaos Kourek, Christos Ntalianis, Argyrios Paraskevaidis, Ioannis |
author_facet | Briasoulis, Alexandros Chasouraki, Angeliki Sianis, Alexandros Panagiotou, Nikolaos Kourek, Christos Ntalianis, Argyrios Paraskevaidis, Ioannis |
author_sort | Briasoulis, Alexandros |
collection | PubMed |
description | Throughout the last decades, newly developed chemotherapeutic agents and immunotherapies that target signaling pathways have provided patients with better prognoses, improved their quality of life and increased survival rates, thus converting cancer to a stable chronic disease. However, non-anthracycline cancer chemotherapy agents and immunotherapies including human epidermal growth factor receptor 2 (HER2) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), proteasome inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells (CAR-T cells) may cause cardiovascular toxicity events and complications that usually interrupt the continuation of an appropriate treatment regimen, which induces life-threatening risks or leads to long-term morbidity. Heart failure, cardiac arrythmias and cardiomyopathies are the most common cardiovascular events related to cardiotoxicity due to chemotherapy. Each patient should be carefully assessed and monitored before, during and after the administration of chemotherapy, to address any predisposing risk factors and the new onset of cardiotoxicity manifestations early and treat them appropriately. The development of novel anticancer agents that cause minimal cardiovascular toxicity events or novel agents that ameliorate the adverse effects of the existing anticancer agents could drastically change the field of cardio-oncology. The aim of this narrative review is to demonstrate new knowledge regarding the screening and diagnosis of non-anthracycline-induced cardiotoxicity and to propose protective measures that could be performed in order to achieve the delivery of optimal care. |
format | Online Article Text |
id | pubmed-8953347 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89533472022-03-26 Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents Briasoulis, Alexandros Chasouraki, Angeliki Sianis, Alexandros Panagiotou, Nikolaos Kourek, Christos Ntalianis, Argyrios Paraskevaidis, Ioannis J Cardiovasc Dev Dis Review Throughout the last decades, newly developed chemotherapeutic agents and immunotherapies that target signaling pathways have provided patients with better prognoses, improved their quality of life and increased survival rates, thus converting cancer to a stable chronic disease. However, non-anthracycline cancer chemotherapy agents and immunotherapies including human epidermal growth factor receptor 2 (HER2) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), proteasome inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells (CAR-T cells) may cause cardiovascular toxicity events and complications that usually interrupt the continuation of an appropriate treatment regimen, which induces life-threatening risks or leads to long-term morbidity. Heart failure, cardiac arrythmias and cardiomyopathies are the most common cardiovascular events related to cardiotoxicity due to chemotherapy. Each patient should be carefully assessed and monitored before, during and after the administration of chemotherapy, to address any predisposing risk factors and the new onset of cardiotoxicity manifestations early and treat them appropriately. The development of novel anticancer agents that cause minimal cardiovascular toxicity events or novel agents that ameliorate the adverse effects of the existing anticancer agents could drastically change the field of cardio-oncology. The aim of this narrative review is to demonstrate new knowledge regarding the screening and diagnosis of non-anthracycline-induced cardiotoxicity and to propose protective measures that could be performed in order to achieve the delivery of optimal care. MDPI 2022-02-23 /pmc/articles/PMC8953347/ /pubmed/35323614 http://dx.doi.org/10.3390/jcdd9030066 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Briasoulis, Alexandros Chasouraki, Angeliki Sianis, Alexandros Panagiotou, Nikolaos Kourek, Christos Ntalianis, Argyrios Paraskevaidis, Ioannis Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents |
title | Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents |
title_full | Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents |
title_fullStr | Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents |
title_full_unstemmed | Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents |
title_short | Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents |
title_sort | cardiotoxicity of non-anthracycline cancer chemotherapy agents |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953347/ https://www.ncbi.nlm.nih.gov/pubmed/35323614 http://dx.doi.org/10.3390/jcdd9030066 |
work_keys_str_mv | AT briasoulisalexandros cardiotoxicityofnonanthracyclinecancerchemotherapyagents AT chasourakiangeliki cardiotoxicityofnonanthracyclinecancerchemotherapyagents AT sianisalexandros cardiotoxicityofnonanthracyclinecancerchemotherapyagents AT panagiotounikolaos cardiotoxicityofnonanthracyclinecancerchemotherapyagents AT kourekchristos cardiotoxicityofnonanthracyclinecancerchemotherapyagents AT ntalianisargyrios cardiotoxicityofnonanthracyclinecancerchemotherapyagents AT paraskevaidisioannis cardiotoxicityofnonanthracyclinecancerchemotherapyagents |